Trial Profile
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms EVEREST; S0931
- 24 Oct 2023 Results from the phase III SWOG S0931 (EVEREST) trial presented at the 48th European Society for Medical Oncology Congress
- 28 Jul 2023 Results evaluating effectiveness of adjuvant Everolimus for renal cell carcinoma, published in the LANCET journal.
- 12 Jul 2023 Planned End Date changed from 1 Jul 2023 to 15 Oct 2026.